2014 In the interests of research rigour, the contested replication study by Baehr et al
Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA
What we need to watch as clinicians: Increased risk of hypoglycemia especially 24 days post-injection when insulin effect peaks Currently indicated for Type 2 Diabetes only T1D trials showed higher hypoglycemia rates Weight gain and injection site reactions remain class effects #Diabetes #Diabetology #InsulinTherapy #Awiqli #InsulinIcodec #NovoNordisk #T2D #DiabetesCare #EndocrinologyUpdate #ClinicalPractice #MedTwitter #HealthcareInnovation To view or add a comment, sign in New research from the QWINT Clinical Trial Program reports on patient experiences with a once-weekly basal insulin compared to daily basal insulin in adults with type 2 diabetes
Partial blockage is not an emergency, so thesurgery to correct it can be planned
The SURPASS program, comprising multiple phase 3 trials in patients with type 2 diabetes, provides evidence regarding tirzepatide's cardiovascular effects, including its impact on heart rate
